TY  - JOUR
U1  - Zeitschriftenartikel, wissenschaftlich - begutachtet (reviewed)
A1  - Winter, Jochen
A1  - Kunze, Rudolf
A1  - Veit, Nadine
A1  - Kuerpig, Stefan
A1  - Meisenheimer, Michael
A1  - Kraus, Dominik
A1  - Glassmann, Alexander
A1  - Probstmeier, Rainer
T1  - Targeting of Glucose Transport and the NAD Pathway in Neuroendocrine Tumor (NET) Cells Reveals New Treatment Options
JF  - Cancers
N2  - Background: the potency of drugs that interfere with glucose metabolism, i.e., glucose transporters (GLUT) and nicotinamide phosphoribosyltransferase (NAMPT) was analyzed in neuroendocrine tumor (NET, BON-1, and QPG-1 cells) and small cell lung cancer (SCLC, GLC-2, and GLC-36 cells) tumor cell lines. (2) Methods: the proliferation and survival rate of tumor cells was significantly affected by the GLUT-inhibitors fasentin and WZB1127, as well as by the NAMPT inhibitors GMX1778 and STF-31. (3) Results: none of the NET cell lines that were treated with NAMPT inhibitors could be rescued with nicotinic acid (usage of the Preiss–Handler salvage pathway), although NAPRT expression could be detected in two NET cell lines. We finally analyzed the specificity of GMX1778 and STF-31 in NET cells in glucose uptake experiments. As previously shown for STF-31 in a panel NET-excluding tumor cell lines, both drugs specifically inhibited glucose uptake at higher (50 μM), but not at lower (5 μM) concentrations. (4) Conclusions: our data suggest that GLUT and especially NAMPT inhibitors are potential candidates for the treatment of NET tumors.
KW  - WZB117
KW  - neuroendocrine
KW  - STF-31
KW  - GMX1778
KW  - glucose uptake inhibitor
KW  - fasentin
UN  - https://nbn-resolving.org/urn:nbn:de:hbz:1044-opus-66405
SN  - 2072-6694
SS  - 2072-6694
U6  - https://doi.org/10.3390/cancers15051415
DO  - https://doi.org/10.3390/cancers15051415
PM  - 36900207
VL  - 15
IS  - 5
SP  - 11
S1  - 11
PB  - MDPI
CY  - Basel
ER  -